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Abstract
Background: Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is an adverse effect of bisphosphonate 
treatment with varying reported incidence rates.
Methods: In two neighboring German cities, prevalence and additional factors of the development of BP-ONJ in 
multiple myeloma patients with bisphosphonates therapy were recorded using a retrospective (RS) and cross-sectional 
study (CSS) design. For the RS, all patients treated from Jan. 2000 - Feb. 2006 were contacted by letter. In the CSS, all 
patients treated from Oct. 2006 - Mar. 2008 had a physical and dental examination. Additionally, a literature review was 
conducted to evaluate all articles reporting on BP-ONJ prevalence. PubMed search terms were: bisphosphonat, 
diphosphonate, osteonecrosis, prevalence and incidence.
Results: In the RS, data from 81 of 161 patients could be obtained; four patients (4.9%) developed BP-ONJ. In the CSS, 
16 of 78 patients (20.5%) developed BP-ONJ. All patients with BP-ONJ had received zoledronate; 12 of these had had 
additional bisphosphonates. All except one had an additional trigger factor (tooth extraction [n = 14], dental surgical 
procedure [n = 2], sharp mylohyoid ridge [n = 3]).
Conclusion: The prevalence of BP-ONJ may have been underestimated to date. The oral examination of all patients in 
this CSS might explain the higher prevalence, since even early asymptomatic stages of BP-ONJ and previously 
unnoticed symptomatic BP-ONJ were recorded. Since nearly all patients with BP-ONJ had an additional trigger factor, 
oral hygiene and dental care might help to reduce BP-ONJ incidence.
Background
Multiple myeloma is characterized by neoplastic prolifer-
ation of plasma cells clones. The most frequent complica-
tions are anemia, renal failure, recurrent bacterial
infections, pathological fractures, and hypercalcemia due
to tumor-induced bone destruction via osteoclastic bone
resorption [1,2].
Bisphosphonates are used in the treatment of multiple
myeloma because of their inhibitory effect on osteoclastic
activity. Depending on the ligands, bisphosphonates are
grouped into nitrogen-containing and non-nitrogen-con-
taining bisphosphonates. The former inhibit the
mevalonate pathway, and the latter are build into the
ATP-molecule; both result in cytotoxic effects to the
osteoclast [3,4].
Bisphosphonates have a beneficial effect on pain and
can reduce fractures in multiple myeloma patients, [5]
thereby increasing quality of life for the patient.
Adverse effects can be separated into four groups:
acute-phase-reactions, upper aerodigestive tract issues
and effects concerning renal function [6]. In 2003, the
fourth adverse effect, bisphosphonate associated
osteonecrosis of the jaw (BP-ONJ), was described for the
first time [7] and has been subsequently diagnosed with
increasing frequency [8].
At first, a causal connection between BP-ONJ and bis-
phosphonates was denied on the grounds that the
patients had additional risk factors for osteonecrosis that
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could explain the higher incidence (cancer, radiation or
chemotherapy, special medications such as steroids,
infections of dental or sinus origin, dental procedures,
anemia or local anesthetics with vasoconstrictors) [9]. In
the meantime, BP-ONJ has been included in the sum-
mary of product characteristics. There is evidence that
the presence of several of these risk factors is related to an
increased risk of developing a BP-ONJ [10].
According to the American Association of Oral- and
Maxillofacial Surgeons (AAOMS), BP-ONJ is defined as
the presence of exposed, necrotic bone in the maxillofa-
cial region that has persisted for more than eight weeks in
a patient with current or previous bisphosphonate ther-
apy and no history of radiation to the jaws [11]. Patients
present with exposed bone, and fistulas to the oral cavity
or external skin. If there is additional infection in the
bone or soft tissues, abscesses, osteolysis and pathologi-
cal fractures may result. Several theories concerning eti-
ology and pathogenesis are currently being discussed in
addition to the suppressed bone turnover theory [12]. Of
particular interest are the antiangiogenic effects of bis-
phosphonates and the possible subsequent development
of avascular osteonecrosis [13], as well as the adverse
impact on the mucosal layer covering the bone via a
proapoptotic effect on keratinocytes [14]. Common
potential trigger factors for the condition have been iden-
tified, the most frequent being a recent dental surgical
procedure such as a tooth extraction. Other seemingly
significant factors include periodontal disease with odon-
toseisis and denture pressure sores [8]. Therapy of BP-
ONJ is difficult and ranges from simple mouth rinses for
asymptomatic exposed bone, to debridement and huge
resections of the mandible or of the maxilla, the latter
having a large impact on the quality of life for effected
patients.
The incidence of the BP-ONJ in multiple myeloma
patients is largely unknown; to date, only a few studies
and one web based survey have been published (see table
1). In most studies, only the patients who reported symp-
toms received an oral exam, rather than all patients at risk
for the condition, thereby potentially underestimating the
magnitude of this side effect.
We conducted two studies in two midsize neighboring
German cities. The aim was to evaluate the prevalence of
BP-ONJ in multiple myeloma patients using two different
study designs and to compare this with existing published
data. Further aims were to detect additional factors that
may be related to the development of BP-ONJ.
Methods
Two studies with two different populations were con-
ducted: one retrospective study and one cross sectional
study. Inclusion criteria for both studies were a diagnosis
of multiple myeloma and bisphosphonate therapy; the
duration of bisphosphonate therapy was not taken into
account. A BP-ONJ case was defined as exposed necrotic
bone existing over a time span of at least eight weeks,
w i t h  n o  r a d i a t i o n  o f  t h e  h e a d  a n d  n e c k  a r e a  i n  t h e
patient's history [11,15].
The retrospective study was conducted in the Depart-
ment of Internal Medicine (Oncology , Hematology and
Palliative Medicine) at the Dr. Horst Schmidt Klinik
Wiesbaden, Germany. Due to an in-house cancer registry,
all patients treated in this clinic suffering from multiple
myeloma are registered. In the study time span from Jan-
uary 2000 to February 2006, 161 patients with multiple
myeloma and bisphosphonate treatment were registered.
All patients were contacted by letter and/or phone; if
contact information was available for their physicians and
dentists, they were contacted as well. In the end, we
obtained data for 81 patients (50.3%). Additional diseases,
medication and risk factors for osteonecrosis were
recorded from patient histories.
The second study had a cross sectional design and was
conducted in the Department of Haematology and
Oncology at the Johannes Gutenberg-University Mainz,
Germany. All 78 patients with multiple myeloma treated
from October 2006 to March 2008, regardless of the date
of diagnosis, were com prised. T he same da ta elements
were collected as in the retrospective study, but patients
in the cross sectional study also underwent an additional
examination (dental and medical) and missing data were
completed. In the oral examination conducted by a den-
tist, the patients were checked for oral hygiene (visible
existence of dental plaque and tartar using the Silness-
Loe plaque index), signs of inflammation, damages to the
oral mucosa and exposed bone.
The protocol was approved by the local ethics commit-
tee: 837.099.06 (5197). Informed consent was obtained
for each patient. No funding was received for this study.
In addition to a descriptive analysis, p-values were cal-
culated with the Mann-Whitney-Test, the Fisher's exact
test and the Pearson's Chi-Quadrate-Test. Statistical anal-
ysis was conducted using SPSS 16 for Windows (SPSS
Inc. Headquarters, Chicago, Illinois).
In addition, Pubmed was queried for literature on BP-
ONJ occurrence. The search was done in December, 2008
using the following search terms: bisphosphonate,
diphosphonate, incidence and prevalence. All papers
reporting on incidence or prevalence of BP-ONJ were
analysed and are reported in Table 1.
Results
Retrospective study
161 patients with multiple myeloma and bisphosphonate
treatment were identified. Data for 81 patients (50%)
could be obtained, 69 had passed away, and 11 either
refused participation or we failed to locate them. The 81Walter et al. Head & Face Medicine 2010, 6:11
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Table 1: Published incidence studies.
Year Author Study 
design
All patients 
orally 
examined
Disease Patients (n) BP-ONJ 
cases
Incidence 
(%)
Used 
bisphosphona
tes in BP-ONJ 
patients
2005 Bamias [24] pros no breast ca 70 2 3 Z, PZ, ZI
mult myel 111 11 10
prostate ca 46 3 7
Durie [25] web survey no mult myel 904 62 6.9 Z,P
breast ca 299 13 4.3
Guarneri [26] retro no breast ca 48 3 6 P
Maerevoet [27] retro no mult myel 194 9 5 P, Z
breast ca
2006 Badros [28] retro yes mult myel 340 11 3.2 P, Z, PZ
Calvo-Villas [29] retro no mult myel 64 7 11 Z
Dimopoulos [30] pros unclear mult myel 202 15 7.4 Z, P, ZP, ZI
Hoff [31] retro no breast ca 1338 16 1.2 P, Z, PZ
mult myel 448 14 3.1
Sanna [32] pros yes breast ca 81 5 6 P, Z
Tosi [33] retro no mult myel 259 9 3.5 Z
Zervas [34] pros no mult myel 254 28 11.0 Z, P, ZP
2007 Aguiar Bujanda [35] css yes breast ca 35 4 11 Z
Corso [36] retro no mult myel 106 8 8 Z, PZ
García Sáenz [37] pros no prostate ca 104 3 3 Z
Jadu [38] retro yes mult myel 655 21 3.2 P
Mavrokki [39] estimation no malignancies 0.9-1.2
Ortega [40] retro no prostate ca 52 6 12 Z
Petrucci [41] unclear no mult myel 311 22 7.1 P, PZ, Z
Wang [15] retro no mult myel 292 11 3.8 Z, P, PZ
breast ca 81 2 3Walter et al. Head & Face Medicine 2010, 6:11
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prostate ca 69 2 3
Wilkinson [42] retro no malignancies 14 349 5.48 Z, P, PZ
2008 Boonyapakorn [22] pros yes mult myel 58 10 17 P, PZ, IZ, Z
Fehm [43] retro no breast ca 233 10 4.3 Z, ICPZ
Ibrahim [44] retro no breast ca 220 5 2.3 PZ, Z
mult myel 59 2 3
Walter [23] css yes prostate ca 43 8 19 IZ, PZ, Z
2009 Walter [45] retro no breast ca 75 4 5.3 Z, PZI
this retrospective study retro no mult myel 81 4 4.9 U, PZ
this cross-sectional study css yes mult myel 78 16 21 Z, PZ, IZ, PZI
All published studies with BP-ONJ incidences compared to the results of these two studies in the last two lines.
Abbreviations: n, number of patients; BP-ONJ, bisphosphonate-associated osteonecrosis of the jaws; css, cross-sectional study; retro, 
retrospective study; ca, cancer; mult myel, multiple myeloma; stage I-III, Durie [16] classification; Z, zoledronate; P, pamidronate; I, ibandronate
Table 1: Published incidence studies. (Continued)
recruited patients (36 women and 45 men) had an aver-
age age of 69.8 years (range 44 - 95 years); the average age
at the time of multiple myeloma diagnosis was 63.7 years
(range 40 - 83 years). All administered bisphosphonates
were nitrogen-containing bisphosphonates. Patients had
been treated for a mean time of 48 months (range 1 -
204). 3% of the patients had received alendronate (70 mg)
per os, 34% had received zoledronate, 26% pamidronate
and 15% ibandronate. For the remaining 12%, the bispho-
sphonate therapy had varied, so that they had received
different bisphosphonates in the course of their treat-
ment (combinations were: pamidronate/zoledronate,
ibandronate/zoledronate and ibandronate/pamidronate/
zoledronate).
Altogether, four patients (5%), three men and one
women aged 53, 71, 74 and 65 respectively, suffered from
bisphosphonate associated osteonecrosis of the jaw. Two
of these patients had only received zoledronate; the other
two patients had been treated with pamidronate followed
by zoledronate for an average duration of 64 months
(range 27 - 128 months). All patients who developed BP-
ONJ in the mandible did so after a tooth had been
removed. All patients with BP-ONJ had been treated with
cytotoxic drugs in addition to bisphosphonates; only one
patient with BP-ONJ was receiving cytotoxic drugs at the
time of BP-ONJ diagnosis. In comparison, 82% of all
patients without BP-ONJ had had chemotherapy. None of
the patients with BP-ONJ smoked, although 8 patients
without BP-ONJ did. 8 patients suffered from diabetes
mellitus but none of them developed BP-ONJ; 9 patients
had further malignant diseases and one developed BP-
ONJ.
Cross sectional study
78 patients (47 men and 31 women) with multiple
myeloma and current bisphosphonate therapy with an
average age of 63.5 years (range 53 - 79 years) at oral
examination had been treated in the specified time span
of 10/06 to 03/08 in the Department of Haematology and
Oncology of the Johannes Gutenberg-University Mainz,
Germany (Table 2). The average age at the time of multi-
ple myeloma diagnosis was 59.8 years (range: 41 -84
years).
According to the multiple myeloma classification of
Durie and Salmon [16], 17 patients were in stage I, 13 in
stage II and 48 patients in stage III. 49 patients had
received only zoledronate, 20 patients had previously
taken pamidronate before receiving zoledronate, six
patients had first received ibandronate followed by zole-
dronate, and three patients had received pamidronate,
zoledronate and ibandroante sequentially. 59 patients
(76%) had been given corticosteroids during their course
of therapy, and 64 patients (82%) had received chemo-
therapy (melphalane, idarubicine, cyclophosphamide,
busulfane, bortezomib, thalidomide, etoposide).
All together, 16 patients (21%) developed BP-ONJ.
These patients had received an average of 48.4 bisphos-Walter et al. Head & Face Medicine 2010, 6:11
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phonate infusions compared to 23.3 infusions in patients
without BP-ONJ. Four of these patients had had only
zoledronate and nine patients had received pamidronate
and zoledronate sequentially; one patient had first
received ibandronate followed by zoledronate; two
patients had pamidronate, zoledronate and ibandronate
sequentially. In 5 patients, BP-ONJ was located in the
mandible, in another 5 patients in the maxilla, and in 6
patients in both jaws. Ten patients had previously had a
tooth extraction at the side of the BP-ONJ; two further
patients had recently undegone a dental surgical proce-
dure, and three patients developed BP-ONJ at the
mylohyoid ridge. In one patient, no possible trigger factor
for ONJ was obvious. 13 of the 16 BO-ONJ patients had
undergone additional chemotherapy and steroids. Three
of these patients had received chemotherapy one or two
months before the BP-ONJ diagnosis. In 10 patients, che-
motherapy had been applied more than 12 months
before. Two patients with and four patients without BP-
ONJ additionally suffered from diabetes mellitus. The
entire group of patients had 9 smokers and 1 developed
BP-ONJ. Three patients without BP-ONJ suffered from
an additional malignant tumor.
Discussion
The aim of these two studies was to evaluate the preva-
lence of BP-ONJ in patients with multiple myeloma and
bisphosphonate therapy.
In the retrospective study, the average age of the
patients at the time of multiple myeloma diagnosis was
63.7 (SD: 10.9) years. In the cross-sectional study the age
was 59.8 (SD: 11.1) years. Both are marginally younger
than that described in the cancer register in Saarland,
Germany, [17] with a peak at the 65-75 year age range and
a median age of disease diagnosis at the range of 60 to 64
years. The median age for multiple myeloma patients in
the United States is 70 years [18]. 4 out of 81 patients (5%)
in the retrospective study and 16 out of 78 (21%) in the
cross sectional study had BP-ONJ.
In both study populations, zoledronate was the bispho-
sphonate most often used. In the cross sectional study, all
patients had received either zoledronate exclusively, or
zoledronate in sequence with other bisphosphonates; the
same is true for 32 out of 72 patients in the retrospective
study. A critical point for the retrospective study design
might be the lack of detection of asymptomatic BP-ONJ
especially as no staging of the disease can be done with
this design. In both studies, all patients who developed
BP-ONJ had received zoledronate at some point during
the course of treatment. The association between zole-
dronate and BP-ONJ is explained by the higher potency
of zoledronate as compared to the other bisphospho-
nates, as well as zoledronate's wide spread use among
cancer patients. Except for one patient in the cross sec-
tional study, all patients showed additional trigger factors
such as tooth extractions (n = 14), dental surgical proce-
dure (n = 2) or a sharp mylohyoid ridge (n = 3), a spot
with a very thin mucous membrane. No further trigger
f a c t o r  c o u l d  b e  d e t e c t e d  f o r  o n l y  o n e  p a t i e n t  w i t h  a
necrosis in the maxilla and the mandible. Chemotherapy
did not show an influence on BP-ONJ prevalence in this
study. It should however be noted that the chemothera-
peutics used were heterogenous and did not allow for a
further subgroup analysis.
Considering the high percentage of cases with an iden-
tifiable trigger factor, a sensible prevention tactic may be
to refer patients with planned bisphosphonate therapy to
a dentist or an oral and maxillofacial surgeon who is
familiar with this kind of disease. This could be analogous
to the management of patients who are about to receive
head and neck radiation [19]. Non-restorable teeth could
be extracted and restorations could be done. After com-
mencement of bisphosphonates therapy, improved oral
hygiene could prevent further dental surgical procedures
such as tooth extractions. Additionally, even currently
asymptomatic exposed necrotic bone might be prevented
from becoming infected. A decrease in BP-ONJ among
patients involved in such a preventive program has
recently been described [20].
Across both studies, the most affected site was the
mandible (9 patients). Six patients had an osteonecrosis
in the mandible as well as in the maxilla, and five patients
had the osteonecrosis in the maxilla only. This skewed
distribution might be explained by the reduced blood
supply in the mandible as compared to the maxilla [21].
All incidence and prevalence studies that have been
published are shown in Table 1. One problem of at least
this retrospective study is the high rate of patients that
was not included in the study and could therefore be a
selection bias. Especially these patients might have had a
severe course of disease and co-morbidities involving fur-
ther medications that might be associated with a greater
odd to develop an osteonecrosis. There are more reasons
that may explain the higher prevalence found in this cross
sectional study as compared to the studies in table 1, the
largest of which may be the study design itself. Due to the
retrospective design of most other studies, complete oral
exams of patients to look for BOJ have rarely been done.
Only Boonyapakorn [22] for multiple myeloma patients
and Walter [23] for prostate cancer patients describe sim-
ilarly high findings with a similar study design. Medical
examinations alone may not be able to detect all cases of
BOJ, particularly those cases of early stage BP-ONJ with
asymptomatic exposed necrotic bone. Dental examina-
tions that focus on BP-ONJ can detect a barely visible
osteonecrosis, for example on the mylohyoid ridge, and
may therefore explain the higher incidences in these stud-
ies. Although there is no statistically significant differ-Walter et al. Head & Face Medicine 2010, 6:11
http://www.head-face-med.com/content/6/1/11
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Table 2: Data of the cross sectional study.
All patients Patients with BP-ONJ Patients without BP-ONJ Difference
Number (percentage) 78 (100%) 16 (21%) 62 (80%)
Age at examination (SD) 63.5 (10.1) 61.9 (21.0) 64.1 (10.5) p = 0.18
Age at MM diagnosis 59.8 (11.1) 54.1 (8.8) 61.3 (11.2) p = 0.02
Men 47 9 38 p = 0.78
Women 31 7 24
MM stage I 17 (22%) 3 (4%) 14 (18%)
MM stage II 13 (17%) 2 (3%) 11 (14%) p = 0.79
MM stage III 48 (62%) 11 (14%) 37 (47%)
Bisphosphonate infusions 28.1 48.4 (range 9 - 111) 23.3 (range 1 - 104) p < 0.001
Zoledronate
Patients 49 (63%) 4 (5%) 45 (58%)
Infusions 15 21 15
Pamidronate + zoledronate
Patients (percentage) 20 (26%) 9 (12%) 11 (14%)
infusions 33, 22 26, 30 39, 15
Ibandronate + zoledronate p = 0.001
Patients (percentage) 6 (8%) 1 (1%) 5 (6%)
infusions 6, 15 4, 28 7, 12
Pamidronate + zoledronate + 
ibandroante
Patients (percentage) 3 (4%) 2 (3%) 1 (%)
infusions 38, 20, 5 27, 28, 3 59, 5, 10
Corticosteroids 59 (76%) 13 (17%) 46 (61%) p = 0.75
Chemotherapy 64 (82%) 13 (17%) 51 (67%) p = 1.0
Diabetes mellitus 6 (8%) 2 (3%) 4 (5%) p = 0.6
Further malignant diseases 3 (4%) 0 3 (4%) p = 1.0
Smoker 8 (10%) 1 (1%) 7 (9%) p = 1.0Walter et al. Head & Face Medicine 2010, 6:11
http://www.head-face-med.com/content/6/1/11
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ence, the prevalence for all retrospective studies for
multiple myeloma ranges from 3 to 11% and for prospec-
tive studies from 7 to, including this study, 21% (p = 0.06).
In studies with such small numbers of patients, the detec-
tion or non detection of a BP-ONJ has a huge influence
on the resulting prevalence or incidence.
Conclusion
The prevalence of BP-ONJ may have been underesti-
mated to date. The oral examination of all patients in this
CSS might explain the higher prevalence, since even early
asymptomatic stages of BP-ONJ and previously unno-
ticed, symptomatic BP-ONJ were recorded. Since nearly
all patients with BP-ONJ had an additional trigger factor,
oral hygiene and dental care might help to reduce BP-
ONJ incidence.
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